Mechanisms regulating PD-L1 expression on tumor and immune cells
Bloomberg (United States) · Sidney Kimmel Comprehensive Cancer Center · +1 more institution
Abstract
The PD-1/PD-L1 checkpoint is a central mediator of immunosuppression in the tumor immune microenvironment (TME) and is primarily associated with IFN-g signaling. To characterize other factors regulating PD-L1 expression on tumor and/or immune cells, we investigated TME-resident cytokines and the role of transcription factors in constitutive and cytokine-induced PD-L1 expression.
Thirty-four cultured human tumor lines [18 melanomas (MEL), 12 renal cell carcinomas (RCC), 3 squamous cell carcinomas of the head and neck (SCCHN), and 1 non-small-cell lung carcinoma (NSCLC)] and peripheral blood monocytes (Monos) were treated with cytokines that we detected in the PD-L1+ TME by gene expression profiling, including IFN-g, IL-1a, IL-10, IL-27 and IL-32g. PD-L1 cell surface protein expression was detected by flow cytometry, and mRNA by quantitative real-time PCR. Total and phosphorylated STAT1, STAT3, and p65 proteins were detected by Western blotting, and the genes encoding these proteins were knocked down with siRNAs. Additionally, the proximal promoter region of PDL1 (CD274) was sequenced in 33 cultured tumors.
Citation impact
- FWCI
- 22.40
- Percentile
- 100%
- References
- 30
Authors
8- SCShuming ChenCorresponding
Bloomberg (United States), Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
- GAGeorge A. Crabill
Bloomberg (United States), Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
- TSTheresa S. Pritchard
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Bloomberg (United States)
- TLTracee L. McMiller
Bloomberg (United States), Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
- PWPing Wei
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Bloomberg (United States)
Topics & keywords
- Immune system
- Cancer research
- Expression (computer science)
- Computational biology
- Biology
- Medicine
- Computer science
- Immunology
- Good health and well-being
Funding
- AAmgen
- BSBristol-Myers Squibb
- MRMelanoma Research Alliance
- JHJohns Hopkins University
- TTTizona Therapeutics
- FPFive Prime Therapeutics
- JTJounce Therapeutics
- NINational Institutes of HealthAwards: R01 AI089830, R01 CA142779, CA142779, NCI R01
- NCNational Cancer InstituteAward: R01 CA142779
- BIBloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University